Of these, 627 patients who showed a suboptimal response after 8 weeks of treatment with olmesartan medoxomil 20 mg/day were randomised to receive olmesartan medoxomil 40 mg/day (n = 302 ...

Following placebo run-in, all patients received olmesartan medoxomil 20 mg/d for 4 weeks. At subsequent 4-week intervals, the regimen was modified in patients with blood pressure >130/85 mm Hg ...

Participants with uncontrolled and otherwise treatment-resistant hypertension showed significant blood pressure improvement ...

Participants taking two BP medications at enrollment were switched to a standardized BP medication regimen consisting of daily indapamide 2.5 mg and olmesartan 40 mg. Participants taking three to ...

ARBs end in the letters "sartan"; examples include Diovan (losartan) and Benicar (olmesartan ... even a small overdose can lead to serious side effects, including kidney failure.

so patients receive systemic anticoagulation to prevent side effects. The main endpoint in the study was the time to first all-cause death, stroke, or major bleeding, and that outcome was seen in ...

ARBs end in the letters "sartan"; examples include Diovan (losartan) and Benicar (olmesartan ... even a small overdose can lead to serious side effects, including kidney failure. Calcineurin ...

There was no history of fever or trauma. She was on antihypertensive (olmesartan 40 mg once daily and amlodipine 5 mg once daily) and antidiabetic (glimepiride 2 mg once daily and metformin 500 mg two ...

The prescribed dosage for phentermine may vary depending on your individual treatment plan. Factors such as your medical history, body weight, and the form of phentermine you’re prescribed may ...

The prescribed dosage for ondansetron may vary depending on a person’s individual treatment plan. Factors such as your medical history and other medications you take may also affect your dosage ...

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...